RU2017110457A3 - - Google Patents

Download PDF

Info

Publication number
RU2017110457A3
RU2017110457A3 RU2017110457A RU2017110457A RU2017110457A3 RU 2017110457 A3 RU2017110457 A3 RU 2017110457A3 RU 2017110457 A RU2017110457 A RU 2017110457A RU 2017110457 A RU2017110457 A RU 2017110457A RU 2017110457 A3 RU2017110457 A3 RU 2017110457A3
Authority
RU
Russia
Application number
RU2017110457A
Other languages
Russian (ru)
Other versions
RU2017110457A (ru
RU2705375C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2017110457A3 publication Critical patent/RU2017110457A3/ru
Publication of RU2017110457A publication Critical patent/RU2017110457A/ru
Application granted granted Critical
Publication of RU2705375C2 publication Critical patent/RU2705375C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2017110457A 2014-01-21 2015-01-20 Фармацевтические композиции, содержащие антибактериальные агенты RU2705375C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN193/MUM/2014 2014-01-21
PCT/IB2015/050421 WO2015110950A1 (en) 2014-01-21 2015-01-20 Pharmaceutical compositions comprising antibacterial agents
IN193MU2014 IN2014MU00193A (enExample) 2014-01-21 2015-01-20

Publications (3)

Publication Number Publication Date
RU2017110457A3 true RU2017110457A3 (enExample) 2018-10-03
RU2017110457A RU2017110457A (ru) 2018-10-03
RU2705375C2 RU2705375C2 (ru) 2019-11-07

Family

ID=52629621

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017110457A RU2705375C2 (ru) 2014-01-21 2015-01-20 Фармацевтические композиции, содержащие антибактериальные агенты

Country Status (10)

Country Link
US (2) US10322116B2 (enExample)
EP (1) EP3217979B8 (enExample)
AU (2) AU2015208830A1 (enExample)
CA (1) CA2954553C (enExample)
ES (1) ES2804500T3 (enExample)
IN (1) IN2014MU00193A (enExample)
NZ (1) NZ728036A (enExample)
RU (1) RU2705375C2 (enExample)
WO (1) WO2015110950A1 (enExample)
ZA (1) ZA201700064B (enExample)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
EP2748165B1 (en) * 2011-08-27 2016-11-02 Wockhardt Limited 1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections.
US8796257B2 (en) * 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
CN104334559B (zh) * 2012-05-30 2017-03-22 明治制果药业株式会社 β‑内酰胺酶抑制剂及其制备方法
RU2676482C2 (ru) * 2013-01-14 2018-12-29 Вокхардт Лимитед Композиции и способы лечения бактериальных инфекций
RU2509560C1 (ru) * 2013-03-22 2014-03-20 Общество С Ограниченной Ответственностью "Валента-Интеллект" Новые терапевтические комбинации миртазапина для применения при болевых расстройствах

Also Published As

Publication number Publication date
ES2804500T3 (es) 2021-02-08
CA2954553C (en) 2022-12-06
RU2017110457A (ru) 2018-10-03
EP3217979A1 (en) 2017-09-20
WO2015110950A1 (en) 2015-07-30
US10322116B2 (en) 2019-06-18
US20180104224A1 (en) 2018-04-19
AU2020201956A1 (en) 2020-04-02
BR112017003444A2 (pt) 2023-03-07
RU2705375C2 (ru) 2019-11-07
AU2020201956B2 (en) 2020-07-09
EP3217979B8 (en) 2020-06-03
EP3217979B1 (en) 2020-04-08
IN2014MU00193A (enExample) 2015-08-28
US20170202813A1 (en) 2017-07-20
CA2954553A1 (en) 2015-07-30
ZA201700064B (en) 2018-08-29
NZ728036A (en) 2019-12-20
AU2015208830A1 (en) 2017-04-27

Similar Documents

Publication Publication Date Title
BR112016017520A2 (enExample)
BR112016016978A2 (enExample)
BR112016018948A2 (enExample)
BR112016018327A2 (enExample)
BR112016015605A2 (enExample)
BR112016018868A2 (enExample)
BR112016018384A2 (enExample)
BR112016018278A2 (enExample)
BR112016018582A2 (enExample)
BR112016018556A2 (enExample)
BR112016015385A2 (enExample)
BR112016018865A2 (enExample)
BR112016017262A2 (enExample)
BR112016008129A2 (enExample)
BR112016016364A2 (enExample)
BR112016014460A2 (enExample)
BR112016017713A2 (enExample)
BR112016016298A2 (enExample)
BR112016018944A2 (enExample)
BR112016015645A2 (enExample)
BR112016000228A2 (enExample)
BR112016016149A2 (enExample)
BR112016018043A2 (enExample)
BR112016015552A2 (enExample)
BR112016017717A2 (enExample)